ArticleClinical & translational immunology2021
Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand.
Article in Clinical & translational immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06939556 (Development of a High-throughput Serological Testing Platform for Mass Screening Purposes of Both Pediatric and Adult Cohorts), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of a High-throughput Serological Testing Platform for Mass Screening Purposes of Both Pediatric and Adult Cohorts
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers.Frontiers in public health · 2023Pooled it
- Evaluation of independent self-collected blood specimens for COVID-19 antibody detection among the US veteran population.Diagnostic microbiology and infectious disease · 2022Trial
- Antibody Transcytosis and Neutralizing Activity in Respiratory Epithelial Cells.bioRxiv : the preprint server for biology · 2026Article
- Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa.BMC medicine · 2026Article
- Quantification of the IgG antibody response half-life for hybrid immunity to SARS-CoV-2.BMC medicine · 2025Article
- Decline of Antibodies to Major Viral and Bacterial Respiratory Pathogens During the COVID-19 Pandemic.The Journal of infectious diseases · 2025Article
- Mechanistic models of humoral kinetics following COVID-19 vaccination.Journal of the Royal Society, Interface · 2025Article
- Article
- RSV Neutralizing Antibodies in Dried Blood.The Journal of infectious diseases · 2024Article
- Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.Scientific reports · 2024Article
- Article
- Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study.Nature communications · 2023Article
- Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19.Microorganisms · 2023Article
- Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy.iScience · 2023Article
- Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023Article
- Seroprevalence of IgG and Subclasses against the Nucleocapsid of SARS-CoV-2 in Health Workers.Viruses · 2023Article
- Cohort profile: A Québec-based plasma donor biobank to study COVID-19 immunity (PlasCoV).BMJ open · 2023Article
- Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.Scientific reports · 2022Article
- Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort.Nature communications · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCirculating antibodies are important markers of previous infection and immunity. Questions remain with respect to the durability and functionality of SARS-CoV-2 antibodies. This study explored antibody responses in recovered COVID-19 patients in a setting where the probability of re-exposure is effectively nil, owing to New Zealand's successful elimination strategy.
methodsA triplex bead-based assay that detects antibody isotype (IgG, IgM and IgA) and subclass (IgG1, IgG2, IgG3 and IgG4) responses against Nucleocapsid (N) protein, the receptor binding domain (RBD) and Spike (S) protein of SARS-CoV-2 was developed. After establishing baseline levels with pre-pandemic control sera (
resultsWhile most individuals had broad isotype and subclass responses to each antigen shortly after infection, only RBD and S protein IgG, as well as NAbs, were relatively stable over the study period, with 99%, 96% and 90% of samples, respectively, having responses over baseline 4-8 months post-infection. Anti-RBD antibodies were strongly correlated with NAbs at all time points (Pearson's
conclusionAntibodies to SARS-CoV-2 persist for up to 8 months following mild-to-moderate infection. This robust response can be attributed to the initial exposure without immune boosting given the lack of community transmission in our setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.